New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol

Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143-0520, USA.
Neuro-Oncology (Impact Factor: 5.56). 05/2008; 10(2):112-20. DOI: 10.1215/15228517-2007-052
Source: PubMed


The blood-brain barrier is a substantial obstacle for delivering anticancer agents to brain tumors, and new strategies for bypassing it are greatly needed for brain-tumor therapy. Intranasal delivery provides a practical, noninvasive method for delivering therapeutic agents to the brain and could provide an alternative to intravenous injection and convection-enhanced delivery. We treated rats bearing intracerebral human tumor xenografts intranasally with GRN163, an oligonucleotide N3'-->P5'thio-phosphoramidate telomerase inhibitor. 3'-Fuorescein isothiocyanate (FITC)-labeled GRN163 was administered intranasally every 2 min as 6 microl drops into alternating sides of the nasal cavity over 22 min. FITC-labeled GRN163 was present in tumor cells at all time points studied, and accumulation of GRN163 peaked at 4 h after delivery. Moreover, GRN163 delivered intranasally, daily for 12 days, significantly prolonged the median survival from 35 days in the control group to 75.5 days in the GRN163-treated group. Thus, intranasal delivery of GRN163 readily bypassed the blood-brain barrier, exhibited favorable tumor uptake, and inhibited tumor growth, leading to a prolonged lifespan for treated rats compared to controls. This delivery approach appears to kill tumor cells selectively, and no toxic effects were noted in normal brain tissue. These data support further development of intranasal delivery of tumor-specific therapeutic agents for brain tumor patients.

Download full-text


Available from: William H. Frey 2nd,

Click to see the full-text of:

Article: New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol

16.31 MB

See full-text
  • Source
    • "The administration of [ 125 I]-labeled insulin-like growth factor-I ( 125 I-IGF-I) has been reported to increase levels of radioactivity in both the olfactory bulb and trigemininal ganglion of the rat brain, with the highest concentrations observed in the latter site (Thorne et al., 2004). In addition, the IN administration of various other products such as lidocaine, stem cells, and telomerase inhibitors have all been shown to reach the brainstem via trigeminal nerve fibers in rodents (Danielyan et al., 2011; Hashizume et al., 2008; Johnson et al., 2010), although it is possible that these substances reach the brainstem via other means such as diffusion though brain CSF via olfactory pathway entry. Notably, projections from the central amygdala and PVN extend to brainstem nuclei that regulate cardiovascular functioning (Viviani et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accumulating evidence demonstrates the important role of oxytocin (OT) in the modulation of social cognition and behavior. This has led many to suggest that the intranasal administration of OT may benefit psychiatric disorders characterized by social dysfunction, such as autism spectrum disorders and schizophrenia. Here, we review nasal anatomy and OT pathways to central and peripheral destinations, along with the impact of OT delivery to these destinations on social behavior and cognition. The primary goal of this review is to describe how these identified pathways may contribute to mechanisms of OT action on social cognition and behavior (that is, modulation of social information processing, anxiolytic effects, increases in approach-behaviors). We propose a two-level model involving three pathways to account for responses observed in both social cognition and behavior after intranasal OT administration and suggest avenues for future research to advance this research field.
    Neuroscience & Biobehavioral Reviews 12/2014; 49. DOI:10.1016/j.neubiorev.2014.12.011 · 8.80 Impact Factor
  • Source
    • "As GRN163L can penetrate plasma membranes through its lipid conjugation, it does not require additional vehicles for its delivery.39 Through intranasal or systemic treatment, both GRN163 and GRN163L can bypass the blood-brain barrier and preferentially affect brain tumor cells with minimum toxicity to normal brain tissue.43,44 These studies provide the basis for using both GRN163 and GRN163L as potent drugs against brain tumors, and both have already reached clinical trial stages. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Telomerase is responsible for maintaining the length of telomeres at the ends of chromosomes. Although most somatic cells do not exhibit telomerase activity, it is reactivated in approximately 85% of cancers. This simple and attractive phenomenon steers the development of anticancer drugs targeting telomeres and telomerase. Recent studies have been revealing extratelomeric roles of telomerase in normal tissues, affecting processes that are critical for survival and aging of organisms. In this review, we will discuss the current therapeutic strategies targeting telomeres and telomerase and evaluate their potential advantages and risks with respect to nontelomeric functions.
    OncoTargets and Therapy 08/2013; 6:1161-1166. DOI:10.2147/OTT.S50918 · 2.31 Impact Factor
  • Source
    • "Intranasal delivery is a promising alternative to standard delivery systems as it provides a practical, painless method for delivering therapeutic agents to the brain (Fig. 3). Rats bearing brain tumors were treated intranasally with an oligonucleotide against Telomerase (TERT).122 The intranasally delivered treatment bypassed the blood-brain barrier, reached the tumor and inhibited tumor growth, leading to a prolonged lifespan in treated rats. "
    [Show abstract] [Hide abstract]
    ABSTRACT: DNA sequences associated with protein-coding genes have been the primary focus of most genetic analyses of complex human diseases. Although we are rapidly gaining a comprehensive view of the etiology of certain central nervous system disorders, major gaps in our understanding persist. Recent studies have uncovered that many human genomic sequences are transcribed but not translated, generating an astounding diversity of noncoding RNAs (ncRNAs). This awareness should be taken into account when studying human diseases and may have profound implications on the development of novel biomarkers as well as therapies.
    RNA biology 06/2012; 9(6):860-70. DOI:10.4161/rna.20482 · 4.97 Impact Factor
Show more